Copyright © 2005, European Society of Cardiology
What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?
Department of Cardiology, Center for Transgene Technology and Gene Therapy, Flemish Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium
Center for Molecular and Vascular Biology, K.U. Leuven, Leuven, Belgium
* Corresponding author. Cardiac Unit and Center for Transgene Technology and Gene Therapy, University of Leuven, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. Tel.: +32 16 344235; fax: +32 16 345990. Email address: stefan.janssens{at}med.kuleuven.be
Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes responsible for extracellular protein degradation in the cardiovascular system. Originally known to play pivotal roles in tissue morphogenesis and wound healing, they have been shown to participate in the complex remodeling processes in blood vessels and the myocardium. The biological activity of MMPs is regulated at different levels: (1) gene expression, (2) activation of precursor proenzyme forms by other MMPs or non-MMP proteins, including thrombin and plasmin, (3) complex formation with surface and extracellular matrix (ECM) components and (4) inhibition by endogenous tissue inhibitors of MMPs, the TIMPs. Murine models with gain or loss of gene function of different MMPs and TIMPS have provided a wealth of experimental data on their critical role in pathological conditions ranging from atherosclerosis, vascular injury, and restenosis to left ventricular function and structural remodeling following chronic pressure and volume overload and ischemia–reperfusion injury.
KEYWORDS Matrix metalloproteinases; Transgenic mice; Left ventricular remodelling; Myocardial infarction; Atherosclerosis; Vascular injury
Time for primary review 14 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Ohshima, A. Petrov, S. Fujimoto, J. Zhou, M. Azure, D. S. Edwards, T. Murohara, N. Narula, S. Tsimikas, and J. Narula Molecular Imaging of Matrix Metalloproteinase Expression in Atherosclerotic Plaques of Mice Deficient in Apolipoprotein E or Low-Density-Lipoprotein Receptor J. Nucl. Med., April 1, 2009; 50(4): 612 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Hermonat, D. Li, B. Yang, and J. L. Mehta Mechanism of action and delivery possibilities for TGF{beta}1 in the treatment of myocardial ischemia Cardiovasc Res, May 1, 2007; 74(2): 235 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Bergman, J. R. Teerlink, R. Mahimkar, L. Li, B.-Q. Zhu, A. Nguyen, S. Dahi, J. S. Karliner, and D. H. Lovett Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1847 - H1860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Westerhof, C. Boer, R. R. Lamberts, and P. Sipkema Cross-talk between cardiac muscle and coronary vasculature. Physiol Rev, October 1, 2006; 86(4): 1263 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Newby, M. Pauschinger, and F. G. Spinale From tadpole tails to transgenic mice: Metalloproteinases have brought about a metamorphosis in our understanding of cardiovascular disease Cardiovasc Res, February 15, 2006; 69(3): 559 - 561. [Full Text] [PDF]
|
|